Patient characteristics
. | Deletion 13q; n = 31 . | No deletion 13q; n = 37 . | P . |
|---|---|---|---|
| Median age, y (range) | 53 (35-65) | 53 (32-65) | .4 |
| Mean β2-microglobulin level, mg/dL (n) | 3.1 (25) | 3.4 (24) | .8 |
| Median no. of prior chemotherapy regimens (range) | 5 (2-13) | 4 (2-10) | .06 |
| Prior high-dose regimen, n (%) | .2 | ||
| None | 3 (10) | 0 | |
| 1 autologous transplantation | 18 (58) | 30 (81) | |
| At least 2 autologous transplantations | 10 (32) | 7 (19) | |
| Relapse to prior high-dose regimen, n (%) | 17 (55) | 21 (57) | .9 |
| Chemotherapy-resistant prior allo-SCT, NC/PD, n (%) | 16 (52) | 18 (49) | .8 |
| No relapse to conventional or high-dose chemotherapy, n (%) | 10 (32) | 13 (35) | .8 |
| Donor, n (%) | .1 | ||
| Unrelated | 17 (55) | 13 (35) | |
| Related | 14 (45) | 24 (65) | |
| Donor sex, n (%) | .5 | ||
| Female | 10 (35) | 15 (41) | |
| Male | 21 (65) | 22 (59) | |
| Sex mismatch, n (%) | 13 (42) | 18 (47) | .6 |
| Patient sex, n (%) | .7 | ||
| Female | 10 (32) | 15 (41) | |
| Male | 21 (68) | 22 (59) | |
| CMV-seropositive recipient, n (%) | 20 (65) | 32 (86) | .03 |
| Graft source, n (%) | .2 | ||
| PBSC | 30 (97) | 33 (89) | |
| BM | 1 (3) | 4 (11) | |
| Median CD34+ cell dose, × 106/kg BW (range) | 5.4 (1.3-13.2) | 5.8 (1.4-13.7) | .3 |
| Median time from diagnosis to allograft, mo (range) | 16 (3-86) | 27 (8-171) | .02 |
| Melphalan/fludarabine, n (%) | 22 (71) | 33 (89) | .8 |
| TBI (2 Gy)/fludarabine/cyclophosphamide | 9 (29) | 4 (11) | .1 |
. | Deletion 13q; n = 31 . | No deletion 13q; n = 37 . | P . |
|---|---|---|---|
| Median age, y (range) | 53 (35-65) | 53 (32-65) | .4 |
| Mean β2-microglobulin level, mg/dL (n) | 3.1 (25) | 3.4 (24) | .8 |
| Median no. of prior chemotherapy regimens (range) | 5 (2-13) | 4 (2-10) | .06 |
| Prior high-dose regimen, n (%) | .2 | ||
| None | 3 (10) | 0 | |
| 1 autologous transplantation | 18 (58) | 30 (81) | |
| At least 2 autologous transplantations | 10 (32) | 7 (19) | |
| Relapse to prior high-dose regimen, n (%) | 17 (55) | 21 (57) | .9 |
| Chemotherapy-resistant prior allo-SCT, NC/PD, n (%) | 16 (52) | 18 (49) | .8 |
| No relapse to conventional or high-dose chemotherapy, n (%) | 10 (32) | 13 (35) | .8 |
| Donor, n (%) | .1 | ||
| Unrelated | 17 (55) | 13 (35) | |
| Related | 14 (45) | 24 (65) | |
| Donor sex, n (%) | .5 | ||
| Female | 10 (35) | 15 (41) | |
| Male | 21 (65) | 22 (59) | |
| Sex mismatch, n (%) | 13 (42) | 18 (47) | .6 |
| Patient sex, n (%) | .7 | ||
| Female | 10 (32) | 15 (41) | |
| Male | 21 (68) | 22 (59) | |
| CMV-seropositive recipient, n (%) | 20 (65) | 32 (86) | .03 |
| Graft source, n (%) | .2 | ||
| PBSC | 30 (97) | 33 (89) | |
| BM | 1 (3) | 4 (11) | |
| Median CD34+ cell dose, × 106/kg BW (range) | 5.4 (1.3-13.2) | 5.8 (1.4-13.7) | .3 |
| Median time from diagnosis to allograft, mo (range) | 16 (3-86) | 27 (8-171) | .02 |
| Melphalan/fludarabine, n (%) | 22 (71) | 33 (89) | .8 |
| TBI (2 Gy)/fludarabine/cyclophosphamide | 9 (29) | 4 (11) | .1 |
PBSC indicates peripheral blood stem cells; SCT, stem cell transplantation; BM, bone marrow; and BW, body weight.